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A SYSTEMATIC REVIEW AND META-ANALYSIS ASSESSING THE RELATIVE 
EFFICACY OF IMMUNE CHECKPOINT INHIBITORS BASED ON PD-L1 
EXPRESSION LEVELS 
Purpose: The purpose was to comprehensively assess the impact of PD-L1 
expression on the efficacy of immune checkpoint inhibitors on Overall Survival (OS) and 
Progression-Free Survival (PFS). 
Methods: A systematic literature search and review was conducted through June 
2019. I searched all eligible randomized controlled trials comparing PD-1/PD-L1 
monotherapy to an active comparator in adult patients with advanced cancer across 
multiple tumor types. The Cochrane risk-of-bias tool was used to assess trial quality. A 
random-effects model was used for the meta-analysis. Heterogeneity was assessed using 
Cochran Q statistic and I2 test.  Publication bias was assessed by visual inspection of a 
funnel plot and Begg’s test.  
Results: I identified and included 23 trials involving 14,434 participants. When 
stratifying PD-L1 positive (+) and negative (-) patients using varying thresholds of 
expression, a significant group difference was observed at PD-L1 >1% ( p=0.04; PD-
L1(+): HR, 0.72; 95% CI, 0.65-0.79; PD-L1(-):  HR,0.83; 95% CI, 0.75-0.91), at PD-L1 
>10% (p=0.02; PD-L1(+): HR,0.50; 95% CI, 0.38-0.62; PD-L1 (-): HR, 0.74; 95% CI, 
0.57-0.90) and at PD-L1>50% (p=0.01; PD-L1(+): HR,0.59; 95% CI, 0.51-0.68; PD-L1(-
): HR, 0.93; 95% CI, 0.71-1.15).  Across tumor types, both PD-L1(+) and PD-L1(-) 
patients treated with an immunotherapy had improved OS compared with patients 
receiving standard care therapies. A PFS benefit was observed and favored patients 
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treated with a PD-1/PD-L1 inhibitor versus standard of care. However, there was 
significant heterogeneity and the benefit on PFS was not statistically significant between 
PD-L1(+) and PD-L1(-) groups using varying cut-off levels of PD-L1 expression. No 
differences between sub-groups of interest including median follow-up time, type of 
inhibitor, and line of therapy for either PD-L1(+) or PD-L1(-) patients at 1% cut-off were 
identified. 
Conclusion: This study supports the use of PD-L1 as a predictive biomarker of 
improved response to immunotherapies. As thresholds increase and specifically above the 
10% PD-L1 expression threshold, patients who were positive for PD-L1 appeared to have 
better OS compared to those who were negative for PD-L1. Further investigation is 
needed to assess the clinical usefulness of PD-L1 at various expression levels with 
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Cancer continues to be a significant cause of human disease, with an estimated 
1.8 million new cases diagnosed in the United States and over 600,000 deaths in the U.S. 
in 2020 (Society, 2020). As cancer is the second leading cause of U.S. deaths, identifying 
improved treatment methods is critical to reducing the extreme burden placed on patients, 
their families, health care systems, and society (CDC, 2016). Within the last five years, 
cancer immunotherapy has emerged as a preferred treatment, demonstrating remarkable 
results in otherwise difficult-to-treat cancer types.  
Immunotherapy is a type of cancer treatment that leverages the body’s natural 
defenses to slow or stop the growth and spread of tumor cells. It also helps the body’s 
immune system kill tumor cells more effectively (Cancer.net, 2019). Resistance to 
immunotherapy is believed to be due to tumor activation of immune-checkpoint 
pathways, which down-modulate immune function and prevent the rejection of cancer 
cells as foreign (Pardoll, 2012). Blockade of these immune checkpoints with antibody 
therapies has been successful in some tumors, enhancing both progression-free survival 
(PFS) and overall survival (OS) (Pardoll, 2012). There are multiple types of 
immunotherapies, and the focus of the current work is monoclonal antibodies, 
specifically programmed cell death protein 1 (PD-1) and programmed death ligand 1 
(PD-L1) checkpoint inhibitors.  
Five PD-1/PD-L1 inhibitors are currently approved by the US Food and Drug 
Administration for the treatment of cancer, including anti-PD-1 antibodies 
(pembrolizumab and nivolumab) and anti-PD-L1 antibodies (atezolizumab, avelumab 
and durvalumab). As outlined in Table 1, approvals span several major cancer types (e.g., 
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melanoma, non-small cell lung cancer (NSCLC), renal, urothelial, and microsatellite 
instability-high colorectal cancer) and specific indications for use (Genentech, 2019; 
Merck & Co, 2020; Pharmaceuiticals, 2020; Serono, 2019; Squibb, 2020). However, 
despite intensive investigation, checkpoint inhibitors have shown limited activity and 
have not been approved in the treatment of many other cancer types including prostate, 
ovarian, pancreatic, and brain.  
Table 1 
FDA Approved Checkpoint Inhibitors 
Drug Target Cancer Types 
KEYTRUDA 
pembrolizumab 
PD-1 Cervical, Colorectal, Endometrial, 
Esophageal, Gastric, Head and Neck, 
Hepatocellular Carcinoma, Hodgkin 
Lymphoma, Melanoma, Merkel Cell, MSI-H, 
NSCLC, Primary Mediastinal Large B-cell 




PD-1 Colorectal carcinoma, head and Neck 
Squamous Cell, Hepatocellular Carcinoma, 
Hodgkin Lymphoma, Melanoma, NSCLC, 
Renal Cell Carcinoma, Urothelial Carcinoma 
TECENTRIQ 
atezolizumab 
PD-L1 NSCLC, SCLC, Triple-Negative Breast 
Cancer, Urothelial Carcinoma 
BAVENCIO 
avelumab 




PD-L1 NSCLC, Urothelial Carcinoma 
 
Notably, while there has been tangible improvement in survival compared to 
chemotherapy, only a subset of patients within each approved indication respond to 
checkpoint therapy. Also, responses to checkpoint inhibitors have been reported outside 
of approved indications, suggesting the potential for new, biomarker-defined indications 
(Carbone, Reck, Paz-Ares, Creelan, Horn, Steins, Felip, van den Heuvel, Ciuleanu, 
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Badin, Ready, Hiltermann, Nair, Juergens, Peters, Minenza, Wrangle, Rodriguez-Abreu, 
Borghaei, Blumenschein, Villaruz, Havel, Krejci, Corral Jaime, Chang, Geese, 
Bhagavatheeswaran, Chen, Socinski, et al., 2017; Panda et al., 2018). Thus, identifying 
and deploying predictive response biomarkers is critical, both to make informed 
treatment decisions in approved indications and potentially to support indication 
expansion (Gibney, Weiner, & Atkins, 2016).  
Several biomarkers have been explored including PD-L1 expression (by 
immunohistochemistry), tumor-infiltrating lymphocytes (such as effector CD8+ T-cells), 
T-cell receptor clonality, tumor mutational load or burden (TMB), microsatellite 
instability status, peripheral blood markers, immune gene signatures, and multiplex 
immunohistochemistry (Gibney et al., 2016). The most well-studied biomarker is PD-L1 
expression, which is approved as a companion or complementary diagnostic for multiple 
checkpoint inhibitors. While PD-L1 expression enriches for response in some indications, 
it is not a perfect biomarker, with many biomarker-positive patients exhibiting little 
treatment response and biomarker-negative patients exhibiting substantial response 
(Borghaei, Paz-Ares, Horn, Spigel, Steins, Ready, Chow, Vokes, Felip, Holgado, Barlesi, 
et al., 2015; Brahmer, Reckamp, Baas, Crinò, et al., 2015; Garon et al., 2015; Larkin, 
Chiarion-Sileni, Gonzalez, Grob, Cowey, Lao, Schadendorf, Dummer, Smylie, 
Rutkowski, Ferrucci, et al., 2015; Mahoney & Atkins, 2014). 
Likewise, multiple antibodies, staining protocols, and evaluation methodologies 
are utilized; e.g. some approaches consider PD-L1 expression only on tumor cells, while 
others consider both tumor and immune-cell expression. Similarly, the use of biomarkers 
beyond PD-L1 to identify patient subgroups likely to respond to checkpoint inhibitors or 
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who will have elevated risk of off-target effects (such as development of an autoimmune 
disease), has not yet identified a conclusive patient stratification biomarker (Gibney et al., 
2016; Topalian, Taube, Anders, & Pardoll, 2016). 
A systematic review and meta-analysis comprehensively assessing the relative 
efficacy of immunotherapies across PD-L1 expression levels across tumor types may 
help us better understand responder status and improve patient selection for these drugs. 
The hypothesis is that across tumor types, elevated PD-L1 expression levels predict an 
increased clinical benefit with exposure to PD-1/PD-L1 inhibitors. 
Anti-PD-1/PD-L1 Monoclonal Antibody Mechanism of Action 
 Scientists have been working for decades to identify immune mechanisms to 
stimulate a response to tumor cells. This has been mostly unsuccessful. The purpose of T 
cells is to destroy infected cells and signal to others to support the immune response. 
However, the systems or pathways that regulate the function of T lymphocytes (aka 
immune checkpoints) that exist to control excessive immune activation also seem to be a 
means for tumors to evade the immune system (Mahoney, Freeman, & McDermott, 
2015).   
 PD-1 is a protein that indirectly effects cell death by interactions with its ligands 
(PD-L1 and PD-L1) (Figure 1). This signaling inhibits or inactivates T cells, which leads 
to reduced proliferation, cytokine production, and cell death (Chen, Irving, & Hodi, 2012; 
Mahoney et al., 2015). Tumor cells express PD-L1, which attaches to PD-1 and B7-1 
receptors on T cells and thereby reduce the immune response (Chen et al., 2012; Keir, 






PD-L1 and PD-1 Mechanism of Action 
 
Note. Adapted with permission from the National Cancer Institute © 2015 Terese Winslow LLC, U.S. 
Govt. 
Multiple tumors have elevated expression of PD-L1, including squamous cell 
carcinoma, colon adenocarcinoma, NSCLC, and breast adenocarcinoma; however, it is 
variable (Mahoney et al., 2015; Patel & Kurzrock, 2015). The recent approach with 
monoclonal antibodies (mAB) is to block the PD-L1 protein so tumor cells are unable to 
inactivate T cells (Chen et al., 2012). All the approved drugs in the anti-PD1/PD-L1 
antibody category (Table 1) target the binding of PD-L1 to PD-1, but as Mahoney & 
Atkins note in their review of the affinity and isotype of the antibody, there are likely 
differences in clinical benefit (Mahoney & Atkins, 2014). 
Pembrolizumab has the highest affinity for PD-1 of any PD-1 inhibitor, which 
may result in the antibody’s ability to be effective at lower dosage or after prolonged 
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periods of stopping therapy (Mahoney et al., 2015). Further support for this notion was 
reported by De Sousa Linhares and colleagues in 2019 (De Sousa Linhares et al., 2019). 
They evaluated the efficacy of the five clinically used PD-1 inhibitors using a functional 
assay (T-cell reporter platform) and found that in vitro pembrolizumab is slightly more 
effective at blocking PD-1 than nivolumab, and that PD-1 antibodies are superior to PD-
L1 antibodies in blocking PD-1 signaling (De Sousa Linhares et al., 2019). 
Clinical Efficacy of PD-1 / PD-L1 Inhibitors 
PD-L1/PD-1 inhibitors have revolutionized cancer care and their associated 
regulatory approvals have led to rapid adoption in clinical practice. Across five solid 
tumor types, Weng and colleagues observed in a recent meta-analysis that use of an 
immunotherapy reduced the risk of death by 31% (hazard ratio [HR]=0.69; 95% CI 0.64–
0.74; P<0.00001) (Weng, Peng, Hu, Yao, & Song, 2018).  
As of February 2020, there were 53 approved indications by FDA across the five 
PD-1/PD-L1 inhibitors (Appendix A) (Genentech, 2019; Merck & Co, 2020; 
Pharmaceuiticals, 2020; Serono, 2019; Squibb, 2020). All are approved in the 
advanced/refractory/metastatic setting, most indications are for combination therapy, and 
16 are for monotherapy. Twenty-three of the approved labels are indicated for the first-
line setting.  
Notably, while improvement in survival compared to chemotherapy is tangible, 
only a subset of patients within each approved indication respond to checkpoint therapy. 
Thus, identification of predictive biomarkers has been a key focus to better understand 
who may benefit from immunotherapy.  
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PD-L1 as a Biomarker of Response 
 PD-L1 is perhaps the most-well studied biomarker and a reasonable choice given 
the mechanism of action of this type of inhibitor. Additionally, PD-L1 is well expressed 
across tumor types, though at variable levels. While cervical cancers and sarcomas are 
noted to have lower expression of PD-L1 (12-29%), others tumor types have a large 
percentage of samples expressing PD-L1 such as thymic (88-100%) or NSCLC with 
considerably variable estimates (20-95%) (Patel & Kurzrock, 2015). PD-L1 is routinely 
ordered by physicians to support immunotherapy decision-making, and PD-L1 positivity 
is currently required in a minority of approved drug labels.   
Clinically, differential PD-L1 expression has been observed to enrich the response 
in some indications and is included as a companion diagnostic in a minority of drug 
labels. For example, Liu reported that in his meta-analysis across some solid tumors, OS 
improved in both PD-L1 positive (PD-L1(+)) patients (1% cut-off) (HR, 0.65; 95% CI, 
0.60-0.70) and PD-L1 negative (PD-L1(-)) patients (HR, 0.82; 95% CI ,0.74-0.91) (Liu et 
al., 2019). This study had limitations including use of trial-level estimates, only patients 
with good performance status (which may have over-estimated treatment effects) 
included, moderate heterogeneity in the PD-L1 (-) group, and across only six tumor types 
(Liu et al., 2019).  
PD-L1 is not a perfect biomarker, as many biomarker-positive patients exhibit 
little treatment response and negative patients frequently exhibit substantial response 
(Borghaei, Paz-Ares, Horn, Spigel, Steins, Ready, Chow, Vokes, Felip, Holgado, Barlesi, 
et al., 2015; Brahmer, Reckamp, Baas, CrinÃ², et al., 2015; Garon et al., 2015; Larkin, 
Chiarion-Sileni, Gonzalez, Grob, Cowey, Lao, Schadendorf, Dummer, Smylie, 
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Rutkowski, Ferrucci, et al., 2015; Mahoney & Atkins, 2014). Multiple factors may 
explain these discordant findings, including PD-L1 tests and their measurement 
variability, aspects of tumor-specific biology and heterogeneity of expression, as well as 
tissue age and quality (Kerr et al., 2015; Remon, Chaput, & Planchard, 2016). 
 PD-L1 expression is typically measured by immunohistochemistry, though 
technical variations include differences in general methods, inclusion of immune cells 
versus tumor cells, antibodies, and cut-off definitions, all which may contribute to the 
variable results of clinical studies.  
Literature Gap 
 If PD-L1 were a perfectly predictive biomarker, we would expect the majority of 
patients who test positive to respond to immunotherapy. Previous meta-analyses of the 
literature indicated a dose-response relationship between PD-L1 expression levels and OS 
benefit beginning at the 1% cut-off across multiple tumor types (Liu et al., 2019; Weng et 
al., 2018).  
In contrast, Davis and colleagues recently reported a meta-analysis of only trials 
used in regulatory filings, identifying significant limitations of using PD-L1 expression as 
a predictive biomarker and concluding that “PD-L1 was predictive in only 28.9% of 
cases, and was either not predictive (53.3%) or not tested (17.8%) in the remaining 
cases”(Davis & Patel, 2019). The authors also noted that this may be an over-estimate, 
because they only included studies that resulted in positive regulatory filings, increasing 
the likelihood that negative results were missed (Davis & Patel, 2019). 
 Based on the vast differences in approved indications and conflicting results 
reported previously, it is reasonable to undertake a systematic review and meta-analysis 
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of the updated literature on randomized clinical trials to comprehensively evaluate the 
utility of PD-L1 as a predictive biomarker to identify patients likely to respond to 
immune therapies targeting the PD-1/PD-L1 checkpoint. The results may help to support 






A comprehensive systematic review and meta-analysis of randomized controlled 
trials was conducted to assess the impact of PD-L1 expression on the efficacy of immune 
checkpoint inhibitors on OS and PFS. An electronic literature search was conducted 
using PubMed, Embase, ClinicalTrials.gov, and the Cochrane controlled trials search, 
separately, from their inception until June 2019. Only English language studies were 
considered. Additionally, as recent studies may be unpublished, electronic searches of the 
two relevant conferences (ASCO and ESMO) were reviewed. Bibliographies of 
published meta-analyses and other randomized controlled trials involving 
immunotherapies were also reviewed. 
The main keywords and search terms included pembrolizumab, nivolumab, 
atezolizumab, avelumab, durvalumab, checkpoint inhibitors, PD-1, PD-L1, and 
randomized controlled trial. The scope of controlled clinical trials was limited to studies 
which assessed PD-1 monotherapy compared to an active therapy regimen in the 
advanced or metastatic solid tumor setting. The specific eligibility criteria are described 
below.  
Eligibility Criteria 
Studies were included based on the following criteria:  
1. Randomized controlled trial 
2. PD-L1 status of included patients (age >18) must be available 
3. PD-L1 measurement and thresholds must be described 
4. Treatment with PD-L1 or PD-1 inhibitors irrespective of dosage and duration 
5. Active comparator  
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6. Any advanced or metastatic solid tumor 
7. Primary endpoint included OS or PFS with hazard ratios available 
8. Publication was available in English  
Studies were excluded based on the following criteria: 
1. PD-L1 expression levels were not described as a sub-group or stratification 
variable  
2. PD-L1 expression results were not assessed with regards to OS or PFS 
3. Studies assessing combination therapy including an immunotherapy   
Data Collection & Quality 
A data-collection form (DCF) was developed in Microsoft Access and piloted 
with two independent reviewers. Discrepancies were resolved and revisions were 
completed prior to starting the systematic review. After final selection of full-text articles 
for analysis, one reviewer independently extracted information from each study. Data 
was quality checked by an independent third party.  
The data collection form included the following variables: NCT number, primary 
author, study acronym, tumor type, trial phase, randomized controlled trial designation, 
sample size, PD-L1 stratification, follow-up duration, PD-L1 assay description, PD-L1 
method, primary outcome measurement, study drug and dosage, comparator drug and 
dosage, schedule, PD-L1 threshold, median age, sex, ECOG status, race, number of 
previous therapies, and outcome measurements. As available the following data for 
outcome measurements were documented by drug, dosage, and PD-L1 status; PFS, OS, 
hazard ratios, and confidence intervals and objective response rates. 
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Additionally, as recent studies may be unpublished, electronic searches of the two 
relevant conferences (ASCO and ESMO) were reviewed to minimize publication bias. 
Analysis Plan 
Analysis Objectives 
 The hypothesis was that across tumor types, as PD-L1 expression levels increase, 
greater clinical benefit will be demonstrated with exposure to PD-1/PD-L1 inhibitors as 
compared to standard-of-care chemotherapy regimens. The primary analysis was the 
difference in OS hazard ratios between PD-L1(+) versus PD-L1(-) patients. The 
secondary analysis was the difference in PFS hazard ratios between PD-L1(+) versus PD-
L1(-) patients. 
Population & Subgroups 
Inclusion and exclusion criteria are listed in the Methods section. However, the 
review includes randomized controlled trials comparing PD-1/PD-L1 monotherapy to an 
active comparator (chemotherapy) in adult patients with advanced cancer across multiple 
tumor types. Subgroup meta-analyses stratified by PD-L1 (+) and PD-L1(-) groups were 
performed to specifically address potential interactions of PD-L1 levels with these 
inhibitors on efficacy measures using the Cochran Q-Statistic. Sub-groups (assessed at 
1% threshold) included immunotherapy inhibitor type (PD-1 vs PD-L1), median duration 
of follow-up (>18months vs <18months), and line of therapy (1st vs later). Two 
sensitivity analyses were completed, including 1) evaluating NSCLC studies separately 
and 2) removal of a single study that used PFS as the primary outcome instead of OS. 





Hazard Ratios and their respective confidence intervals for OS and PFS were used 
and reported separately by PD-L1 expression status. PFS is typically defined as the time 
from randomization in a clinical trial to disease progression or death from any cause. OS 
is defined as the time from randomization to death from any cause.  
Handling of Missing Values and Other Data Conventions 
Variables are summarized for all studies with available data. For key outcome 
variables, the proportion of missing data (i.e., if only PD-L1 positive groups are included 
in a study) will be described to understand the extent to which there may be under-
reporting or bias. 
Assessment of Risk of Bias  
The Cochrane risk-of-bias tool (RoB2) was used to assess the quality of included 
randomized controlled trials (Sterne JAC, 2019). The tool assessed data across five 
domains, including randomization process, deviations from intended interventions, 
missing outcome data, measurement of outcomes, and selection of reported results. These 
domains are evaluated using signaling questions, weighted and summarized as low, some, 
or high concern of bias. Publication bias was assessed by visual inspection of a funnel 
plot (Egger, BMJ 1997) and using Begg’s test for funnel plot asymmetry (Begg and 
Mazumdar, Biometrics 1994). Risk of small study effect was assessed for both OS and 
PFS outcomes for PD-L1 studies included in 1% cut-off analyses.  
Descriptive Analysis 
Summary tables were created to describe study characteristics, including study 
name, author, tumor type, phase, PD-L1 stratification, therapy line, sample size, median 
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duration of follow-up, PD-L1 staining type, percentage of males, percentage of ECOG 0 
or 1 patients included, percent white, drug names and dosage, PD-L1 expression levels, 
and the primary outcome. Categorical variables (PD-L1 stratification, 1st line therapy 
studies, median follow-up, PD-L1 staining type and cut-offs) were summarized using the 
number and percentage of studies falling into each category.  
Statistical Procedures 
Analyses performed 
The meta-analysis assessed both OS and PFS endpoint and was performed for all 
included studies combining all tumor types. A random-effects model based on the 
restricted maximum likelihood method was performed to combine the HRs from 
individual trial data using the approach defined by Hardy and Thompson (Hardy & 
Thompson, 1996). Primary meta-analysis methods using Stata metaan commands are also 
described in Palmer and Sterne’s updated journal collection (Palmer, 2016). The meta 
summarize, subgroup command was used to report individual effect sizes and the overall 
effect size, their confidence intervals, heterogeneity statistics including a test of group 
differences, and with the meta forestplot command as graphical display. The test of group 
differences or interaction aims to determine if there is a difference in effect sizes between 
the sub-groups and is expressed using Q. The reml command was used to denote the 
restricted maximum likelihood method. All meta-analyses were sub-grouped according to 
their PD-L1 positivity level to understand any difference between positive versus 
negative biomarker status at various cut-offs (1%, 5%, 10%, and 50%). Additional sub-
group meta-analyses for OS were completed for all tumor types at the 1% PD-L1 
positivity threshold with regard to type of drug (PD-L1 vs PD-1), 1st line vs. later study, 
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and median duration of follow-up (>18months vs <18months) separately for PD-L1(+) 
and PD-L1(-) patients. 
Between trial heterogeneity was assessed using Cochran Q statistic and the degree 
using I2 test (Higgins & Thompson, Statistics in Medicine, 2002). The 
Cochrane Q test (P < 0.05) indicated a high level of statistical heterogeneity and the 
percentage of I2 of 25%, 50%, and 75% corresponding to low, moderate, and high 
degrees of heterogeneity, respectively.  
Sensitivity analyses were conducted within the OS analysis at 1% and 5% 
thresholds by removing one study with PFS as its primary endpoint. Additionally, 
analyses were conducted separately for NSCLC to better understand any differences in 
that specific tumor type.   
Statistical Programs 
Stata version 16 (StataCorp LP, College Station, TX, USA) was used for all 
statistical analyses. A two-tailed P < 0.05 was considered statistically significant unless 






Systematic Review Results 
The search consisted of all studies published by June 2019 with complete results 
available. A total of 3,618 records were identified in the initial search across PubMed, 
Embase, and Cochrane Clinical Trials which included abstracts from ESMO and ASCO. 
Only 46 articles remained after preliminary screening of titles and abstracts, and 23 
studies were finally included after full text review in the current systematic review and 
meta-analysis. Studies were removed for various reasons, including lack of overall 
survival endpoint data, study of combination therapy regimens, and absence of PD-L1-
specific information. Across these 23 studies, 14,434 patients were represented. Ten 
studies focused on NSCLC, five on melanoma, and the remaining studies concerned head 
and neck, gastric, urothelial, and colorectal cancers. All studies were industry funded. 
Figure 2 




The majority of studies were unblinded randomized controlled phase 3 trials, with 
the exception of two randomized phase 2 trials. Thirteen of the 24 studies were stratified 
by PD-L1 status. Seven studies were executed in the front-line setting, with the remainder 
being second-line or later. Studies averaged a total sample size of 682 patients with the 
majority gender being male (mean = 66%). For studies reporting ECOG status, the mean 
proportion of patients with a performance status of ECOG O was 40% and ECOG 1 mean 
was 58%. Only 10 studies reported race, and most of their patients were white (mean = 
76%). Median age was 61.6 years and median follow-up time for endpoint assessment 
ranged from 7.3 months to 28 months.  
Each randomized controlled trial compared a PD-1/PD-L1 monotherapy to 
standard-of-care options such as investigator choice of chemotherapy regimen or 
ipilimumab for patients with melanoma. Immunotherapies represented in this systematic 
review included two studies with avelumab (10mg/kg every 2 weeks [Q2W]), four 
studies with atezolizumab (1,200mg Q2W and Q3W), nine studies with nivolumab 
(3mg/kg Q2W), and eight studies with pembrolizumab (across multiple doses of 200mg, 
2mg/kg, and 10mg/kg all Q3W schedule).  
 PD-L1 assessments were run on immunohistochemistry assays, mostly central 
laboratory assessments and included the following manufacturers: IHC 73-10 pharmDx, 
IHC 22C3 pharmDx, IHC Dako 28-8, and Ventana SP142. Of our 23 studies, 21 stained 
using tumor proportion score (TPS) versus combined proportion score (CPS).     
 Twenty-one studies included OS as a primary endpoint, and the other two used 
PFS. Six studies had co-primary endpoints of PFS and OS. The strategies for 
incorporation of PD-L1 cut-offs varied significantly between studies. Seventeen studies 
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included at least 1% as their PD-L1 cut-off and reported various endpoint analyses for the 
remaining endpoints. Over half of the studies stratified on PD-L1 variable within their 
studies; 16 of the studies allowed all-comers, while 7 studies excluded those that did not 
meet a specific PD-L1 cut-off. Individual study summary characteristics are listed in 
Table 2 and Table 3 (Bang et al., 2018; Barlesi et al., 2018; Bellmunt et al., 2017; 
Borghaei, Paz-Ares, Horn, Spigel, Steins, Ready, Chow, Vokes, Felip, Holgado, & et al., 
2015; Brahmer, Reckamp, Baas, CrinÃ², et al., 2015; Carbone, Reck, Paz-Ares, Creelan, 
Horn, Steins, Felip, Van Den Heuvel, Ciuleanu, Badin, Ready, Hiltermann, Nair, 
Juergens, Peters, Minenza, Wrangle, Rodriguez-Abreu, Borghaei, Blumenschein, 
Villaruz, Havel, Krejci, Corral Jaime, Chang, Geese, Bhagavatheeswaran, Chen, & 
Socinski, 2017; Cohen et al., 2019; Eng et al., 2019; Fehrenbacher et al., 2016; 
Fehrenbacher et al., 2018; Ferris et al., 2018; Hamid et al., 2017; Herbst et al., 2019; 
Larkin, Chiarion-Sileni, Gonzalez, Grob, Cowey, Lao, Schadendorf, Dummer, Smylie, 
Rutkowski, & et al., 2015; Mok et al., 2019; Motzer et al., 2015; Powles et al., 2018; 
Reck et al., 2019; Reck et al., 2016; Robert et al., 2015; Schachter et al., 2017; Shitara et 






Overall Study Characteristics of the Included 23 Randomized Controlled Trials 
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Patient Demographics of the Included 23 Randomized Controlled Trials 




ECOG0 %ECOG1 ECOG1 %White White Age (Median) 
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Regarding PD-L1 positivity, the reported PD-L1 expression levels varied across 
studies and their accompanying impact on clinical benefit. Among PD-L1(+) patients, 
58% of studies at the 1% cut-off, 73% of studies at 5% cut-off, 60% of studies at 10% 
cut-off, and 78% of studies at the 50% cut-off showed statistically significant results, 
with OS benefit from a PD-1/PD-L1 monotherapy compared to standard of care. In 
contrast, regarding PD-L1(-) patients, 15% of studies at the 1% cut-off, 29% of studies at 
5% cut-off, 25% of studies at 10% cut-off, and zero studies at the 50% cut-off (n=1) 
observed statistically significant results with a clinical benefit over the standard of care. 
Risk of Bias Assessment 
The Cochrane risk-of-bias 2 tool (RoB2) was used to assess the quality of the 
included randomized controlled trials. All the trials had low risk for bias due to 
inappropriate measures of outcomes and/or missing outcome data. The randomization 
process was reported in all trials, and there were no deviations from intended 
interventions in trials that may have affected outcomes. None of the trials showed a high 
probability of selection bias in the reported results. Overall, there was low risk of bias, 
given that 17 of the 23 studies were indicated as low risk based on the individual domains 













Figure 3  
Cochrane Risk of Bias (Per protocol) Summary by Domains 
 
 Though some tumor measurements were assessed by unblinded assessors, biased 
results were very unlikely. It was also observed that there were generally more dropouts 
prior to dosing in chemo groups versus immunotherapy groups, though this was also 
unlikely to affect study outcomes. Line output is available in Appendix B. 
Meta-Analysis Results – Overall Survival (OS) 
 Using a random-effects model based on the restricted maximum likelihood 
method, HRs from individual trial data were combined. All meta-analyses were grouped 
according to their PD-L1 positivity level to detect any difference between positive versus 
negative biomarker status at various thresholds (1%, 5%, 10%, and 50%). Summary 
tables and forest plots are used to illustrate results from individual trials and the meta-
analyses. All meta-analysis code, tables, and forest plot results are included in Appendix 
C.  
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 Seventeen studies had available data for OS analysis at the 1% PD-L1 threshold 
across all solid tumors. The pooled estimate of PD-L1(+) effect at 1% threshold was 0.72 
(95% CI 0.65-0.79). The pooled estimate of PD-L1(-) effect at 1% threshold was 0.83 
(95% CI 0.75-0.91). A considerable level of heterogeneity was observed in the PD-L1(+) 
group (I2 = 55.56%) and there was a modest yet statistically significant difference 
between the PD-L1(+) and PD-L1(-) groups (p=0.04). Figure 4 illustrates the Forest Plot 






















Overall Survival by PD-L1 Positivity using 1% Threshold Across All Tumors 
 





 No significant interaction was observed between PD-L1 positive and negative 
groups at the 5% PD-L1 threshold, although the survival benefit appears numerically 
better in PD-L1(+) patients than in PD-L1(-) patients. At the 10% PD-L1 threshold, the 
survival benefit is statistically significant and larger in PD-L1(+) patients than in PD-L1(-
) patients (P =0.02). At the 50% threshold, any interpretation of group differences when 
stratifying between positive and negative groups should be approached with caution, as 
only one study presented data for negative patients; however, statistical significance was 
observed. Heterogeneity was not calculable in the negative group and was moderate in 
the positive group (I2=32.29%). Table 4 summarizes the OS results using hazard ratios 
grouped by PD-L1 expression thresholds. 
Table 4 
Summary Table of Overall Survival Results by PD-L1 Expression Threshold 
PD-L1 
Threshold 
  Overall Survival HR (95% CI)   
Studies 
(N) 
PD-L1(+) PD-L1(-) Interaction 
1% 17 0.72 (95% CI 0.65-0.79) 0.83 (95% CI 0.75-0.91) p=0.04 
5% 11 0.61 (95% CI 0.48-0.74)  0.76 (95% CI 0.57-0.95)  p=0.21 
10% 5 0.50 (95% CI 0.38-0.62) 0.74 (95% CI 0.57-0.90) p=0.02 
50% 8 0.59 (95% CI 0.51-0.68) 0.93 (95% CI 0.71-1.15) p=0.01 
 
Subgroup Analysis – OS 
 Subgroup analyses were conducted at 1% PD-L1 expression thresholds for 
inhibitor type (PD-L1 versus PD-1), duration of follow-up (>18mon vs <18mon), and 





any of the sub-groups assessed (Table 5). Only one study used CPS vs TPS as the 
specific cell staining methodology, thus subgroup analyses were not performed.  
Table 5 
Sub-group Analysis for Overall Survival at 1% PD-L1 Threshold 
Sub-Group Overall Survival HR (95% CI) 
PD-L1(+) PD-L1(-) 
PD-1 Inhibitor 0.70 (95% CI 0.61-0.79) 0.78 (95% CI 0.69-0.88)  
PD-L1 Inhibitor 0.78 (95% CI 0.65-0.90) 1.05 (95% CI 0.76-1.35) 
<18M Follow-up 0.78 (95% CI 0.65-0.90) 0.90 (95% CI 0.67-1.13) 
>18M Follow-up 0.70 (95% CI 0.61-0.79)  0.82 (95% CI 0.72-0.92) 
1st Line 0.76 (95% CI 0.55-0.97)  0.78 (95% CI 0.58-0.98)  
2nd or later 0.70 (95% CI 0.63-0.77) 0.86 (95% CI 0.74-0.98)  
 
Sensitivity Analyses – OS  
 Sensitivity analyses were conducted at the PD-L1 thresholds of 1% and 5% with 
an attempt to explain heterogeneity in the positive group. CheckMate 026 was removed 
from the analysis, as it was the only study that had PFS as the primary endpoint, but also 
reported OS.  This removal resulted in a reduction of 14% and 22% heterogeneity at the 
1% and 5% thresholds, respectively (Appendix C – Tables 11 and 12). 
 Additionally, we limited the meta-analysis to NSCLC using the same random-
effects analysis. There were insufficient data to assess OS within melanoma as a single 
tumor type. Table 13 in Appendix C illustrates an OS benefit seen in all NSCLC patients 
treated with immunotherapy vs standard of care; however, there was no statistically 
significant difference between PD-L1(+) and negative patients (p=0.47). A considerable 





Meta-Analysis Results – Progression-Free Survival 
 No differences were observed between PD-L1 positive and negative groups at any 
of the thresholds analyzed using PFS as the outcome of interest, though considerable 
heterogeneity was identified at each threshold. A summary table of results is presented 
below. 
Table 6 
Summary Table of Progression-Free Survival Results by PD-L1 Expression Threshold 
PD-L1 
Threshold 
  Progression Free Survival HR (95% CI)   
Studies 
(N) PD-L1(+) PD-L1(-) Interaction 
1% 17 0.81 (95% CI 0.67-0.95)  1.12 (95% CI 0.82-1.42)  p=0.06 
5% 7 0.72 (95% CI 0.51-0.92) 0.84 (95% CI 0.40-1.28) p=0.61  
10% 10 0.57 (95% CI 0.42-0.73) 0.80 (95% CI 0.39-1.21) p=0.32 
 
 Due to the significant heterogeneity across studies and lack of significance in 
differential response across positive and negative PD-L1 groups, PFS sub-group analyses 
were not attempted.  
Publication Bias 
Publication bias for Overall Survival (1% cut-off for determining PD-L1 (+) and 
PD-L1 (-) groups) was assessed by visual inspection of a funnel plot and Begg’s test for 
symmetry. Statistically significant publication bias was observed (Prob > |z| = 0.05) for 
PD-L1 (-) results. However, no statistically significant publication bias was observed for 








Figure 5  
Publication Bias Funnel Plot using Overall Survival Outcome at 1% PD-L1 threshold for 
negative patients 
 
Figure 6  
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Publication bias for PFS (1% cut-off for both PD-L1 positive and negative 
groups) was also assessed by visual inspection of a funnel plot and Begg’s test. 
Statistically significant publication bias was found (Prob > |z| = 0.01) for PD-L1 (-) 
results. However, no statistically significant publication bias was observed for PD-L1 (+) 
groups (Prob > |z| = 0.19). Funnel plots are below in Figures 7 and 8. 
Figure 7  
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Figure 8  
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The results of this study support the use of PD-L1 as a biomarker of improved 
response to immunotherapies. As thresholds increase and specifically above the 10% PD-
L1 expression threshold, patients who are positive for PD-L1 appeared to have better OS 
compared to negative PD-L1 patients at the 10% threshold. This also supports the 
majority of the findings in the literature across tumor types, i.e., both PD-L1(+) and PD-
L1(-) patients treated with PD-1/PD-L1 monotherapy have an improved OS over 
standard-of-care therapies (Genentech, 2019; Liu et al., 2019; Merck & Co, 2020; 
Pharmaceuiticals, 2020; Serono, 2019; Squibb, 2020; Weng et al., 2018; Zhang et al., 
2016). The clinical benefit was seen in PFS as well for immunotherapies versus standard 
of care, though no interaction effect for PD-L1 levels was observed.  
Using the 5% PD-L1 threshold to separate groups, no statistically significant 
difference was observed, though the groups were different numerically. While a 
significant difference was observed between PD-L1 positive and negative groups at 1% 
for all tumors, a moderate level of heterogeneity among studies was identified in the 
positive group; thus, all differences cannot be attributed to the PD-L1 group. 
Furthermore, no differences were identified between sub-groups of interest, including 
median follow-up time, type of inhibitor, and line of therapy for either PD-L1(+) or PD-
L1(-) patients at 1% cut-off.  
 A sensitivity analysis was completed to assess potential sources of heterogeneity 
by removing the single study (CheckMate 26) that was powered for PFS outcome; 
however, that study also reported OS. This explained 22% of the heterogeneity within the 





Within the 1% group, this sensitivity analysis explained 14% of the differences and 
further increased the statistical difference between the two groups. 
 PD-L1 expression is variable across tumor types however, an improved response 
to immunotherapy was seen across tumor types. Though there were insufficient studies to 
limit to melanoma, a sensitivity analysis limited to NSCLC revealed no difference 
between PD-L1 positive and negative groups, supporting the hypothesis of clinical 
benefit outside of this tumor type.  
 A PFS benefit was observed in PD-L1 positive patients at the thresholds analyzed 
and favored patients treated with a PD-1/PD-L1 inhibitor versus standard of care. 
However, there was significant heterogeneity, and no interaction between positive and 
negative groups was observed. Any interpretation of PFS analyses should be limited.  
 Immunohistochemistry (IHC) is the standard method for PD-L1 assessment. 
However, one recent study indicated a 100-fold difference in analytic sensitivity across 
reagents used for IHC, and another indicated an inter-rater reliability of assessing PD-L1 
at the 1% level between 77% and 80% (Marchetti et al., 2017; Sompuram, Vani, 
Schaedle, Balasubramanian, & Bogen, 2018). This is clinically important, as low-level 
results may be affected by test manufacturer and individual pathology review. This also 
may contribute to the variability in findings at the 1% and to a lesser extent the 5% cut-
off levels. Scoring methodologies in previous trials may also contribute to variability, as 
TPS included only tumor cells, and CPS included both tumor and immune cells. 
However, all but two of the studies included in this analysis used TPS as its staining and 





Measurement of PD-L1 expression could be improved by the use of next-
generation sequencing technologies such as RNA-seq, to more reliably measure PD-L1 
levels in tumor specimens. Conroy and colleagues recently used RNA-seq to assess 
analytical and clinical performance of detecting PD-L1 as compared to IHC and 
concluded it was comparable in performance and “had advantages of being amenable to 
standardization and avoidance of interpretation bias” (Conroy et al., 2019).  
Though previous meta-analyses indicated a positive dose-response effect by PD-
L1 expression thresholds, the study by Liu et al. assessed only nivolumab and involved 
1,738 patients as compared to the current study, which includes over 14,000 (Liu et al., 
2019). However, the study also had less variability in their testing methodologies, which 
may have limited bias and improved their ability to detect differences across all 
thresholds analyzed (Liu et al., 2019). Zhang and colleagues observed that PD-L1 
positive patients had greater clinical benefit compared to PD-L1 negative patients when 
combining multiple thresholds in their sub-group analysis. The study included less than 
half the number of patients in the current study, as well as hematologic malignancies and 
patients treated with combination therapy (Zhang et al., 2016). 
 PD-L1 is now a routinely tested clinical biomarker. However, FDA approvals for 
PD-L1 specific indications are limited to 10 of the 53 approved, given the overall greater 
benefit of immunotherapy versus standard of care in advanced solid tumors. However, 
not all tumor types are approved for treatment with immunotherapy. PD-L1 is required 
only in indications held by pembrolizumab or atezolizumab within cervical, esophageal, 
gastric, head and neck, NSCLC, TNBC, and urothelial cancer. Given the improved 





others, additional clinical trials are warranted in patients who have high PD-L1 
expression, are outside of the approved indications, or who have very few therapeutic 
options for treatment of their advanced cancer.  
 The strengths of this study include its large sample size (over 14,000 patients) and 
up-to-date inclusion of all randomized clinical trials, as this is a fast-paced clinical 
development space. Another strength is the strict inclusion criteria of including only PD-
1/PD-L1 monotherapies against an active comparator in the phase III setting, with 96% of 
studies powered for long-term OS as its primary endpoint. Combined with rigorous 
statistical methods, this study may provide relevant information to support further study 
of PD-L1 as a predictive biomarker in the clinical immunotherapy setting of patients with 
advanced solid tumors.  
This systematic review also has limitations. Only one reviewer selected the full-
text articles for inclusion, which may have biased selection. However, the articles 
selected were also reviewed against other meta-analyses, significant overlap was noted, 
and all data points for analysis were quality checked by a third party. Additionally, due to 
the considerable heterogeneity identified across all included trials or those in sub-groups, 
a random effects model was used. No significant publication bias was identified, although 
this specific analysis was underpowered, it suggests the usefulness of these results in 
evaluating the clinical impact of using PD-L1 as a predictive biomarker. Additionally, no 
trials included in this study reported co-factors that are likely contributors to PD-L1 
variability, including pathologist variability, tissue age and quality, and specimen 
collection site. Further study is warranted to explore the impact of these potential co-





Using the GRADE (Grading of Recommendations, Assessment, Development and 
Evaluations) guidelines (Guyatt GH et al. BMJ, 2008) to rate the quality of the evidence 
for PD-L1 as a biomarker, which at higher thresholds indicate an improved response to 
immunotherapies, the strength of evidence is assessed to be high. Studies conducted to 
date resulting in the approvals of immunotherapies have been randomized controlled 
trials using active comparators with low risk of bias. While there is some heterogeneity 
across studies assessing different tumor types, measurement tools, and other pre-specified 
factors, the outcomes of interest and patient populations are similar with sufficient power 
to detect differences. Additionally, publication bias is estimated to be low, and there is 







In conclusion, this systematic review and meta-analysis of randomized controlled 
trials support the use of PD-L1 as a predictive biomarker of improved response to 
immunotherapies. As thresholds increase, and specifically above the 10% PD-L1 
expression threshold, patients who are positive for PD-L1 appeared to have better OS as 
compared to those negative for PD-L1. Further investigation is needed to assess the 
clinical usefulness of PD-L1 at various expression levels with different technologies that 
may have reduced random or systematic measurement error variability. Additional 
randomized trials, especially among patients with unapproved tumor types and higher 
levels (>10%) of PD-L1 expression, are warranted to provide further evidence regarding 





























For the treatment of patients with 
recurrent or metastatic cervical 
cancer with disease progression on 
or after chemotherapy whose 
tumors express PD-L1 [Combined 
Positive Score (CPS) ≥1] as 
determined by an FDA-approved 
test 
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For the treatment of adult and 
pediatric patients with unresectable 
or metastatic, microsatellite 
instability-high (MSI-H) or 
mismatch repair deficient colorectal 
cancer that has progressed 
following treatment with a 























Adult and pediatric (12 years and 
older) patients with microsatellite 
instability-high (MSI-H) or 
mismatch repair deficient (dMMR) 
metastatic colorectal cancer that has 
progressed following treatment with 
a fluoropyrimidine, oxaliplatin, and 
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have disease progression following 
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For the treatment of patients with 
recurrent locally advanced or 
metastatic squamous cell carcinoma 
of the esophagus whose tumors 
express PD-L1 [Combined Positive 
Score (CPS) ≥10] as determined by 
an FDA-approved test, with disease 
progression after one or more prior 
lines of systemic therapy 
Yes 
after one or more 
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KEYTRUDA pembrolizumab Gastric Cancer  
For the treatment of patients with 
recurrent locally advanced or 
metastatic gastric or 
gastroesophageal junction 
adenocarcinoma whose tumors 
express PD-L1 [Combined Positive 
Score (CPS) ≥1] as determined by 
an FDA approved test, with disease 
progression on or after 2 or more 
prior lines of therapy including 
fluoropyrimidine- and platinum-
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FU for the first-line treatment of 
patients with metastatic or with 
unresectable, recurrent HNSCC 
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treatment of patients with metastatic 
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≥1] as determined by an FDA-
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As a single agent for the treatment 
of patients with recurrent or 
metastatic HNSCC with disease 
progression on or after platinum-
containing chemotherapy 
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Patients with recurrent or metastatic 
squamous cell carcinoma of the 
head and neck with disease 
progression on or after a platinum-















For the treatment of patients with 
HCC who have been previously 
treated with sorafenib 










Patients with hepatocellular 
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For the treatment of adult and 
pediatric patients with refractory 
cHL, or who have relapsed after 3 
or more prior lines of therapy 
No 
who have relapsed 
after 3 or more 













Adult patients with classical 
Hodgkin lymphoma that has 
relapsed or progressed after 
autologous hematopoietic stem cell 


























Adult patients with classical 
Hodgkin lymphoma that has 
relapsed or progressed after 3 or 
more lines of systemic therapy that 
includes autologous HSCT. 
No 













KEYTRUDA pembrolizumab Melanoma 
For the adjuvant treatment of 
patients with melanoma with 
involvement of lymph node(s) 
following complete resection 
No none none 









KEYTRUDA pembrolizumab Melanoma 
For the treatment of patients with 
unresectable or metastatic 
melanoma 







OPDIVO nivolumab Melanoma 
Patients with melanoma with lymph 
node involvement or metastatic 
disease who have undergone 
complete resection, in the adjuvant 
setting 








OPDIVO nivolumab Melanoma 
Patients with unresectable or 
metastatic melanoma, as a single 
agent or in combination with 
ipilimumab 















Adults and pediatric patients 12 
years and older with metastatic 















For the treatment of adult and 
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High Cancer  
For the treatment of adult and 
pediatric patients with unresectable 
or metastatic, microsatellite 
instability-high (MSI-H) or 
mismatch repair deficient solid 
tumors that have progressed 
following prior treatment and who 
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following concurrent platinum-
based chemotherapy and radiation 
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In combination with carboplatin and 
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As a single agent for the first-line 
treatment of patients with NSCLC 
expressing PD-L1 [Tumor 
Proportion Score (TPS) ≥1%] as 
determined by an FDA-approved 
test, with no EGFR or ALK 
genomic tumor aberrations, and is 
metastatic. 









As a single agent for the treatment 
of patients with metastatic NSCLC 
whose tumors express PD-L1 (TPS 
≥1%) as determined by an FDA-
approved test, with disease 
progression on or after platinum-
containing chemotherapy.  
Yes 













In combination with pemetrexed 
and platinum chemotherapy, as 
first-line treatment of patients with 
metastatic nonsquamous NSCLC, 









NSCLC, with no 
















As a single agent for the first-line 
treatment of patients with NSCLC 
expressing PD-L1 [Tumor 
Proportion Score (TPS) ≥1%] as 
determined by an FDA-approved 
test, with no EGFR or ALK 
genomic tumor aberrations, and is 
stage III where patients are not 
candidates for surgical resection or 
definitive chemoradiation 
Yes none none 
stage III where 















Patients with metastatic non-small 
cell lung cancer and progression on 














Patients with metastatic small cell 
lung cancer with progression after 
platinum-based chemotherapy and 













 for the treatment of adult patients 
with metastatic NSCLC who have 













In combination with bevacizumab, 
paclitaxel, and carboplatin, for the 



















with metastatic non-squamous 
NSCLC with no EGFR or ALK 
genomic tumor aberrations 








in combination with paclitaxel 
protein-bound and carboplatin for 
the first-line treatment of adult 
patients with metastatic non-
squamous NSCLC with no EGFR or 








NSCLC with no 













For the treatment of adult and 
pediatric patients with refractory 
PMBCL, or who have relapsed after 
2 or more prior lines of therapy 
No 
who have relapsed 
after 2 or more 















First-line treatment, in combination 
with axitinib of patients with 
advanced renal cell carcinoma 
(RCC) 










In combination with axitinib, for the 
first-line treatment of patients with 
advanced RCC 








Patients with advanced renal cell 

















Patients with intermediate or poor 
risk, previously untreated advanced 
renal cell carcinoma, in combination 
with ipilimumab 













For the treatment of patients with 
metastatic SCLC with disease 
progression on or after platinum-
based chemotherapy and at least one 
other prior line of therapy 
No 





at least one other 
prior line of 
therapyining 
chemotherapy.  










In combination with carboplatin and 
etoposide, for the first-line 
treatment of adult patients with 



















In combination with paclitaxel 
protein-bound for the treatment of 
adult patients with unresectable 
locally advanced or metastatic 
TNBC whose tumors express PD-
L1 (PD-L1 stained tumor-
infiltrating immune cells [IC] of any 
















tumor area), as determined by an 





Patients with locally advanced or 
metastatic urothelial carcinoma 
(UC) who have disease progression 
during or following platinum-
containing chemotherapy 













Patients with locally advanced or 
metastatic urothelial carcinoma 
(UC) who have disease progression 
within 12 months of neoadjuvant or 
adjuvant treatment with platinum-
containing chemotherapy 













Locally advanced or metastatic 
urothelial carcinoma who have 
disease progression during or 
following platinum-containing 
chemotherapy 













Locally advanced or metastatic 
urothelial carcinoma who have 
disease progression within 12 
months of neoadjuvant or adjuvant 
treatment with platinum-containing 
chemotherapy 

















For the treatment of patients with 
locally advanced or metastatic 
urothelial carcinoma who have 
disease progression during or 
following platinum-containing 
chemotherapy or within 12 months 
of neoadjuvant or adjuvant 








within 12 months 
















For the treatment of patients with 
locally advanced or metastatic 
urothelial carcinoma who are not 
eligible for cisplatin containing 
chemotherapy and whose tumors 
express PD-L1 [Combined Positive 
Score (CPS) ≥10] as determined by 
an FDA-approved test, or in patients 
who are not eligible for any 
platinum-containing chemotherapy 
regardless of PD-L1 status 
Yes 
not eligible for 
cisplatincontaining 
chemotherapy or 



















For the treatment of patients with 
Bacillus Calmette-Guerin (BCG)-
unresponsive, high-risk, non-muscle 
invasive bladder cancer (NMIBC) 
with carcinoma in situ (CIS) with or 
without papillary tumors who are 
ineligible for or have elected not to 
undergo cystectomy 
No 
ineligible for or 












carcinoma in situ 












Patients with locally advanced or 
metastatic urothelial carcinoma who 




















Patients with locally advanced or 
metastatic urothelial carcinoma who 
have disease progression within 12 
months of neoadjuvant or adjuvant 























For the treatment of adult patients 
with locally advanced or metastatic 
urothelial carcinoma who are not 
eligible for cisplatin-containing 
chemotherapy and whose tumors 
express PD-L1 (PD-L1 stained 
tumorinfiltrating immune cells [IC] 
covering ≥ 5% of the tumor area), 
as determined by an FDA-approved 
test 











For the treatment of adult patients 
with locally advanced or metastatic 
urothelial carcinoma who are not 
eligible for any platinum-containing 
chemotherapy regardless of PD-L1 
status 











For the treatment of adult patients 
with locally advanced or metastatic 
urothelial carcinoma who have 
disease progression during or 
following any platinum-containing 
chemotherapy, or within 12 months 
of neoadjuvant or adjuvant 
chemotherapy. 
















Unique ID 1 Study ID NCT02392172 Assessor KK 
 




Aim adhering to intervention (the 'per-protocol' effect) 
 
The effect of adhering to 
intervention… 
 
failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned 
intervention by trial participants 
Experimental avelumab Comparator docetaxel Source Journal article(s) with results of the trial 
Outcome Overall Survival (TPS @ 1%) Results HR 0.9 95% CI 0.72-1.12 Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? N 
 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? Y 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? Y 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? N A small difference seen in subjects randomized & received a dose was observced between groups. Unlikely to impact study 
outcome. 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? Y 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? N 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N PD-L1 measurements established at central laboratory 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  






Unique ID 2 Study ID NCT02256436 Assessor KK 
 




Aim adhering to intervention (the 'per-protocol' effect) 
 
The effect of adhering to 
intervention… 
 
failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention 
by trial participants 
Experimental pembrolizumab Comparator IC Chemo Source Journal article(s) with results of the trial 
Outcome OS @ 10% CPS Results HR 0.57 95%CI .37-.88 Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? N 
 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? Y 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? Y 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? N a single digit difference seen in subjects randomized & received a dose was observced between groups. Unlikely to impact 
study 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? Y 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? N 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N PD-L1 measurements established at central laboratory 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  













Unique ID 3 Study ID NCT02613507 Assessor KK 
Ref or Label Wu Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention 
by trial participants 
Experimental nivolumab Comparator docetaxel Source Journal article(s) with results of the trial 
Outcome OS @ 1% PD-L1 Results HR 0.62 95%CI 0.45-0.87 Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? N 
 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? Y 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? Y 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? N a single digit difference seen in subjects randomized & received a dose was observced between groups. Unlikely to impact 
study 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? Y 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? N 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
 




PD-L1 expression was prospectively assessed from archived tumor tissue or recent biopsy in a central laboratory before patient 
randomization. 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  













Unique ID 4 Study ID NCT02625623 Assessor KK 
Ref or Label Bang Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention 
by trial participants 
Experimental avelumab Comparator IC Chemo Source 
 
Outcome OS @ 1% PD-L1 Results HR 0.94 95%CI 0.57-1.55 Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? N 
 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? Y 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? Y 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? N single digit difference observed in fall-out from randomization to dosing between groups. Unlikely to bias outcomes. 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? Y 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? N 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N PD-L1 retrospectively assessed at central laboratory 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  







Unique ID 5 Study ID NCT02105636 Assessor KK 
Ref or Label Ferris Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention by 
trial participants 
Experimental nivolumab Comparator IC Chemo Source Journal article(s) with results of the trial 
Outcome OS Results HR 0.68 95%CI 0.54-0.86 Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? N 
 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? Y 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? Y 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? N 
 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? Y 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? N 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N Tumor PD-L1 membrane expression was evaluated centrally by means of IHC 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low Fresh or archived pretreatment tumor specimens were obtained after the last therapy and before trial entry from 90.6% of the 
patients. 








Unique ID 6 Study ID NCT01642004 Assessor KK 
Ref or Label Brahmer Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention by 
trial participants 
Experimental nivolumab Comparator docetaxel Source Journal article(s) with results of the trial 
Outcome OS @ 1% Results HR 0.69 95%CI 0.45-1.05 Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? PN 
patients were generally well□ 
balanced between the groups, with slight between-□ 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? PY 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? PY 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? N 
 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? PY 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? N 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N PD-L1 centrally assessed 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  






Unique ID 7 Study ID NCT01668784 Assessor KK 
Ref or Label Motzer Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention by 
trial participants 
Experimental nivolumab Comparator everolimus Source Journal article(s) with results of the trial 
Outcome OS @ 1% PD-L1 Results HR 0.79 95%CI 0.53-1.17 Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? N 
 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? Y 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? Y 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? N 
 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? Y 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? N 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N PD-L1 measurements centrally completed 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  







Unique ID 8 Study ID NCT02041533 Assessor KK 
Ref or Label Carbone Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention by 
trial participants 
Experimental nivolumab Comparator IC chemo Source Journal article(s) with results of the trial 
Outcome OS @ 1% Results HR 1.07 95%CI 0.86-1.33 Weight 1 





Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
 
 




Among all the patients, the baseline characteristics were generally balanced between the treatment groups. 
However, in the nivolumab group, the percentage of women was lower than that in the chemotherapy group (32% vs. 45%), as 
was the percentage of patients with a PD-L1 expression level of 50% or more (32% vs. 47%); the percentage of patients with 
liver metastases was slightly higher in the nivolumab group (20% vs. 13%). In addition, patients in the nivolumab group had a 
greater tumor burden (on the basis of the median sum of target-lesion diameters) than those in the chemotherapy group. 







Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? Y 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? Y 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? N 
 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? Y 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? N 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N PD-L1 Centrally assessed 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  






Unique ID 9 Study ID NCT01721746 Assessor KK 
Ref or Label Weber Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention by 
trial participants 
Experimental nivolumab Comparator IC Chemo Source Journal article(s) with results of the trial 
Outcome OS @ 5% PD-L1 Results HR 0.73 95%CI 0.49-1.09 Weight 1 





Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
 









Baseline characteristics were similar in the nivolumab and ICC study groups, with the exception of history of brain metastases 
and high lactate dehydrogenase, which were higher in the nivolumab than the ICC group. Additionally, patients were heavily 
treated, with half of all 
randomly allocated patients receiving at least two previous systemic therapies. The proportion of patients receiving previous 
immunotherapies other than ipilimumab was also higher in the ICC than the nivolumab group. The type and extent of previous 
treatments were generally consistent 
between treatment groups. 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? Y 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? Y 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? N 
 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 4 vs 31 (nivo vs doce) did not recieve a dose, however unlikely to biat outcome. 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? N radiologists were blinded to treatment for tumor size measurements 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? NA 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N PD-L1 centrally assessed and assessors were unaware of group assignment 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  






Unique ID 10 Study ID NCT01673867 Assessor KK 
Ref or Label Borghei Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention by 
trial participants 
Experimental nivolumab Comparator docetaxel Source Journal article(s) with results of the trial 
Outcome OS @ 1% PD-L1 Results HR 0.58 95% CI 0.43-0.79 Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? PY 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? N The baseline characteristics were balanced between the treatment groups, with slight between-group imbalances in the 
percentages of male patients and patients younger than 65 years of age. 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? Y 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? Y 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? N Five patients in the nivolumab group and 22 in the docetaxel group did not receive the assigned study drug 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? Y 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? PN 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N Central lab assessment of PD-L1 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  







Unique ID 11 Study ID NCT01721772 Assessor KK 
Ref or Label Robert Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention 
by trial participants 
Experimental nivolumab Comparator dacarbazine Source Journal article(s) with results of the trial 
Outcome OS @ 5% PD-L1 Results HR 0.3 95%CI 0.15-0.60 Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? N 
 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? Y 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? Y 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? N 
 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? PY 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? N 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N PD-L1 done centrally and prospectively 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  







Unique ID 12 Study ID NCT01844505 Assessor KK 
Ref or Label Larkin Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention by 
trial participants 
Experimental nivolumab Comparator ipilmumab Source Journal article(s) with results of the trial 
Outcome OS @ 5% PD-L1 Results HR NA Median NR 95% CI 39.1 - NR Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? N 
 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? N 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? N 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? N 
 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? N 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? NA 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N Prospective and centrally assessed PD-L1 measurements 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  







Unique ID 13 Study ID NCT02788279 Assessor KK 
Ref or Label Eng Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention 
by trial participants 
Experimental atezolizumab Comparator regorafenib Source Journal article(s) with results of the trial 
Outcome ORR @5% PD-L1 TILS Results ORR 3% Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? N 
 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? Y 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? Y 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? N single digit differences between groups in who received treatment post randomization. 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? PY 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? N 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N central analysis of PD-L1 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  







Unique ID 14 Study ID NCT02302807 Assessor KK 
Ref or Label Powles Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention by 
trial participants 
Experimental atezolizumab Comparator IC Chemo Source Journal article(s) with results of the trial 
Outcome OS @ 5% PD-L1 IC2/3 Results HR .87 95%CI 0.63-1.21 Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? N 
 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? Y 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? Y 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? N small numerical differences between groups regarding who declined participation after randomization 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? PY 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? N 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N PD-L1 assessed centrally 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  







Unique ID 15 Study ID NCT01704287 Assessor KK 
Ref or Label Hamid Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention by 
trial participants 
Experimental pembrolizumab Comparator IC Chemo Source Journal article(s) with results of the trial 
Outcome PFS @ 1% PD-L1 Results HR 0.52 95%CI 0.39-0.68 Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? N 
 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? N 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? N 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? N 
 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? N 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? NA 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N 
 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  







Unique ID 16 Study ID NCT01866319 Assessor KK 
Ref or Label Robert Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention by 
trial participants 
Experimental pembrolizumab Comparator ipilimumab Source Journal article(s) with results of the trial 
Outcome OS @ 1% PD-L1 Results Median 35.6 95%CI 29.3-NR Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? N 
 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? PY 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? PY 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? PN 
 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? PN 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? PY 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? N 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N 
 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  







Unique ID 17 Study ID NCT01905657 Assessor KK 
Ref or Label Herbst Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention by 
trial participants 
Experimental pembrolizumab Comparator docetaxel Source Journal article(s) with results of the trial 
Outcome OS @ 1% PD-L1 Results HR 0.66 95%CI 0.57-0.77 Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? N 
 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? Y 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? Y 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? PN Some numerical differences in dropouts from randomization to first dose between groups 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? Y 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? N 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N PD-L1 assessed centrally 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  







Unique ID 18 Study ID NCT02142738 Assessor KK 
Ref or Label Reck Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention by 
trial participants 
Experimental pembrolizumab Comparator IC Chemo Source Journal article(s) with results of the trial 
Outcome OS @ 50% PD-L1 Results HR 0.63 95% CI 0.47-0.86 Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? 
 
PN Generally similar although more patients in the chemotherapy group than in the pembrolizumab group had never smoked (12.6% 
vs. 3.2%) and more patients in the pembrolizumab group than in the chemotherapy group had brain metastases (11.7% vs. 
6.6%). These differences were not statistically significant. 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? Y 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? Y 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? PN 
 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? PN 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? N 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? NA 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N PD-L1 centrally assessed 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  







Unique ID 19 Study ID NCT02252042 Assessor KK 
Ref or Label Cohen, E Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention by 
trial participants 
Experimental pembrolizumab Comparator IC Chemo Source Journal article(s) with results of the trial 
Outcome OS @50% PD-L1 Results HR 0.53 95%CI 0.35-0.81 Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? N 
 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? Y 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? Y 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? PN 10 on Chemo arm withdrew consent prior to dosing versus 1 in pembro group. Unlikely to impact outcomes 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? N 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? NA 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N 
 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  






Unique ID 20 Study ID NCT02370498 Assessor KK 
Ref or Label Shitara Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention by 
trial participants 
Experimental pembrolizumab Comparator paclitaxel Source Journal article(s) with results of the trial 
Outcome OS @ 1CPS Results HR 0.82 95%CI 0.66-1.03 Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? PN more patients in paclitaxel group were >65. Some differences in histological subtypes 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? Y 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? Y 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? PN 20 patients dropped out of paclitaxel group prior to dosing versus 2 in pembro group 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? N 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? NA 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N 
 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  







Unique ID 21 Study ID NCT02220894 Assessor KK 
Ref or Label Mok Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention by 
trial participants 
Experimental pembrolizumab Comparator IC Chemo Source Journal article(s) with results of the trial 
Outcome OS @ 1% TPS Results HR 0.81 95%CI 0.71-0.93 Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? N 
 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? Y 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? Y 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? PN Over 60 subjects in chemo group withdrew consent prior to dosing as compared to zero in pembro group 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? N 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? NA 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N 
 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  







Unique ID 22 Study ID NCT02008227 Assessor KK 
 
Ref or Label Fehrenbacher Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention 
by trial participants 
Experimental atezolizumab Comparator docetaxel Source 
 
Outcome OS @ 1% PD-L1 Results HR 0.77 95%CI 0.64-0.92 Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? N 
 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? Y 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? Y 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? PN 30 subjects dropped prior to dosing with docetaxel versus a fraction for pembro 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? PN 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? NA 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N 
 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  










Unique ID 23 Study ID NCT01903993 Assessor KK 
Ref or Label Fehrebacher Aim adhering to intervention (the 'per-protocol' effect) 
The effect of adhering to 
intervention… failures in implementing the intervention that could have affected the outcome; non-adherence to their assigned intervention by 
trial participants 
Experimental atezolizumab Comparator docetaxel Source Journal article(s) with results of the trial 
Outcome OS @ 1% TPS Results HR 0.59 95% CI 0.4-0.85 Weight 1 




Bias arising from the 
randomization process 
1.1 Was the allocation sequence random? Y 
 
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? Y 
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? PN Baseline characteristics were balanced between groups, except for an 11% 
greater proportion of female patients in the docetaxel group (35% in the 
atezolizumab group vs 47% in the docetaxel group; 






Bias due to deviations 
from intended 
interventions 
2.1 Were participants aware of their assigned intervention during the trial? Y 
 
2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? Y 
2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups? NA 
 
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome? N 
 
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes? N 
 
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the 
intervention? NA 
 





Bias due to missing 
outcome data 
3.1 Were data for this outcome available for all, or nearly all, participants randomized? Y 
 
3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? NA 
 
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? NA 
 
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? NA 






Bias in measurement of 
the outcome 
4.1 Was the method of measuring the outcome inappropriate? N 
 
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? N 
 
4.3 Were outcome assessors aware of the intervention received by study participants? PY 
 
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? PN 
 
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? NA 




Bias in selection of the 
reported result 
5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before 
unblinded outcome data were available for analysis? Y 
 
5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain? N 
 
5.3 ... multiple eligible analyses of the data? N 
 
Risk of bias judgement Low  








Overall Survival Results 
Table C-1 
Overall Survival by PD-L1 Positivity using 1% Threshold Across All Tumors
 Test of group differences: Q_b = chi2(1) = 4.08            Prob > Q_b = 0.043
                                                                             
       Overall        27      54.81   0.001       0.011      49.97       2.00
                                                                             
           Yes        15      31.53   0.007       0.011      55.56       2.25
            No        11      16.99   0.108       0.000       0.00       1.00
                                                                             
         Group        df          Q   P > Q        tau2       % I2         H2
                                                                             
Heterogeneity summary
                                                                      
              theta            0.759       0.699       0.820
Overall              
                                                                      
              theta            0.718       0.646       0.790
                     
       CheckMate 25            0.790       0.470       1.110      2.49
             POPLAR            0.590       0.365       0.815      3.87
                OAK            0.770       0.630       0.910      5.79
        KEYNOTE-042            0.810       0.700       0.920      6.57
        KEYNOTE 010            0.660       0.560       0.760      6.83
       CheckMate 57            0.590       0.395       0.785      4.47
       CheckMate 26            1.070       0.835       1.305      3.69
      CheckMate 017            0.690       0.390       0.990      2.72
      CheckMate 078            0.620       0.410       0.830      4.16
   JAVELIN Lung 200            0.900       0.700       1.100      4.36
        KEYNOTE 006            0.670       0.515       0.825      5.41
      Checkmate 067            0.530       0.380       0.680      5.53
      CheckMate 141            0.550       0.355       0.745      4.47
        KEYNOTE-061            0.820       0.635       1.005      4.69
JAVELIN Gastric 300            0.940       0.450       1.430      1.28
        Imblaze 370            0.800       0.310       1.290      1.28
Group: Yes           
                                                                      
              theta            0.829       0.749       0.909
                     
       CheckMate 25            0.770       0.585       0.955      4.69
             POPLAR            1.040       0.475       1.605      1.00
                OAK            0.840       0.670       1.010      5.04
       CheckMate 57            0.900       0.610       1.190      2.85
      CheckMate 017            0.580       0.305       0.855      3.05
      CheckMate 078            0.750       0.465       1.035      2.92
        KEYNOTE 006            0.790       0.440       1.140      2.19
      Checkmate 067            0.770       0.525       1.015      3.52
      CheckMate 141            0.730       0.430       1.030      2.72
        KEYNOTE-061            1.200       0.830       1.570      2.01
JAVELIN Gastric 300            1.220       0.855       1.585      2.06
        Imblaze 370            1.810       0.770       2.850      0.32
Group: No            
                                                                      
              Study               HR    [95% Conf. Interval]  % Weight




Subgroup meta-analysis summary              Number of studies =     28
        Study label:  Study
          Std. Err.:  _meta_se
        Effect size:  OS_HR
  Effect-size label:  HR











Test of group differences: Q_b = chi2(1) = 1.55            Prob > Q_b = 0.213
                                                                             
       Overall        15      45.08   0.000       0.032      68.96       3.22
                                                                             
           Yes         9      26.90   0.001       0.030      66.95       3.03
            No         5      15.72   0.008       0.038      71.10       3.46
                                                                             
         Group        df          Q   P > Q        tau2       % I2         H2
                                                                             
Heterogeneity summary
                                                                    
            theta            0.663       0.554       0.772
Overall            
                                                                    
            theta            0.610       0.477       0.744
                   
    CheckMate 037            0.730       0.430       1.030      5.54
    CheckMate 066            0.300       0.075       0.525      6.79
       Imvigor211            0.870       0.580       1.160      5.70
    Checkmate 067            0.630       0.360       0.900      6.02
    CheckMate 141            0.500       0.235       0.765      6.11
           POPLAR            0.540       0.260       0.820      5.86
              OAK            0.640       0.465       0.815      7.67
     CheckMate 26            1.020       0.770       1.270      6.36
    CheckMate 017            0.530       0.240       0.820      5.70
     CheckMate 57            0.430       0.265       0.595      7.84
Group: Yes         
                                                                    
            theta            0.758       0.567       0.949
                   
    CheckMate 037            1.150       0.750       1.550      4.18
    CheckMate 066            0.480       0.285       0.675      7.32
    Checkmate 067            0.620       0.470       0.770      8.09
    CheckMate 141            0.810       0.480       1.140      5.09
    CheckMate 017            0.700       0.425       0.975      5.94
     CheckMate 57            1.010       0.725       1.295      5.78
Group: No          
                                                                    
            Study               HR    [95% Conf. Interval]  % Weight




Subgroup meta-analysis summary            Number of studies =     16
        Study label:  Study
          Std. Err.:  _meta_se
        Effect size:  OS_HR
  Effect-size label:  HR






Overall Survival by PD-L1 Positivity using 5% Threshold Across All Tumors
 



















Test of group differences: Q_b = chi2(1) = 5.14            Prob > Q_b = 0.023
                                                                             
       Overall         8      16.05   0.042       0.016      51.37       2.06
                                                                             
           Yes         4       3.19   0.527       0.001       7.09       1.08
            No         3       6.10   0.107       0.014      50.64       2.03
                                                                             
         Group        df          Q   P > Q        tau2       % I2         H2
                                                                             
Heterogeneity summary
                                                                    
            theta            0.628       0.509       0.746
Overall            
                                                                    
            theta            0.501       0.382       0.620
                   
    Checkmate 072            0.710       0.360       1.060      7.67
    CheckMate 141            0.560       0.210       0.910      7.67
    CheckMate 017            0.500       0.195       0.805      9.14
     CheckMate 57            0.400       0.235       0.565     15.99
      KEYNOTE-045            0.570       0.315       0.825     11.18
Group: Yes         
                                                                    
            theta            0.737       0.571       0.903
                   
    Checkmate 074            0.610       0.465       0.755     17.20
    CheckMate 141            0.730       0.450       1.010     10.10
    CheckMate 017            0.700       0.435       0.965     10.74
     CheckMate 57            1.000       0.725       1.275     10.31
Group: No          
                                                                    
            Study               HR    [95% Conf. Interval]  % Weight




Subgroup meta-analysis summary            Number of studies =      9
        Study label:  Study
          Std. Err.:  _meta_se
        Effect size:  OS_HR
  Effect-size label:  HR






Overall Survival by PD-L1 Positivity using 10% Threshold Across All Tumors
 






















Test of group differences: Q_b = chi2(1) = 7.78            Prob > Q_b = 0.005
                                                                             
       Overall         8      19.12   0.014       0.014      59.20       2.45
                                                                             
           Yes         7      10.61   0.157       0.005      32.29       1.48
            No         0       0.00       .       0.000          .          .
                                                                             
         Group        df          Q   P > Q        tau2       % I2         H2
                                                                             
Heterogeneity summary
                                                                    
            theta            0.635       0.529       0.741
Overall            
                                                                    
            theta            0.594       0.509       0.679
                   
           POPLAR            0.490       0.065       0.915      4.77
              OAK            0.450       0.260       0.640     12.29
      KEYNOTE-042            0.690       0.545       0.835     14.71
      KEYNOTE-040            0.530       0.300       0.760     10.39
      KEYNOTE-024            0.630       0.435       0.825     12.04
      KEYNOTE 010            0.500       0.375       0.625     15.83
     CheckMate 26            0.900       0.570       1.230      6.85
 JAVELIN Lung 200            0.670       0.480       0.860     12.29
Group: Yes         
                                                                    
            theta            0.930       0.710       1.150
                   
      KEYNOTE-040            0.930       0.710       1.150     10.84
Group: No          
                                                                    
            Study               HR    [95% Conf. Interval]  % Weight




Subgroup meta-analysis summary            Number of studies =      9
        Study label:  Study
          Std. Err.:  _meta_se
        Effect size:  OS_HR
  Effect-size label:  HR






Overall Survival by PD-L1 Positivity using 50% Threshold Across All Tumors
 













Overall Survival Sub-Group Analysis 
Table C-5 
Overall Survival for PD-L1 Negative Patients using 1% Threshold Across All Tumors 




Test of group differences: Q_b = chi2(1) = 2.95            Prob > Q_b = 0.086
                                                                             
       Overall        11      16.99   0.108       0.000       0.00       1.00
                                                                             
           Yes         7       7.80   0.351       0.000       0.00       1.00
            No         3       6.39   0.094       0.041      49.38       1.98
                                                                             
         Group        df          Q   P > Q        tau2       % I2         H2
                                                                             
Heterogeneity summary
                                                                      
              theta            0.829       0.749       0.909
Overall              
                                                                      
              theta            0.785       0.690       0.880
                     
        KEYNOTE-061            1.200       0.830       1.570      4.68
        KEYNOTE 006            0.790       0.440       1.140      5.23
      Checkmate 067            0.770       0.525       1.015     10.68
       CheckMate 57            0.900       0.610       1.190      7.62
       CheckMate 25            0.770       0.585       0.955     18.72
      CheckMate 017            0.580       0.305       0.855      8.47
      CheckMate 141            0.730       0.430       1.030      7.12
      CheckMate 078            0.750       0.465       1.035      7.89
Group: Yes           
                                                                      
              theta            1.054       0.762       1.345
                     
             POPLAR            1.040       0.475       1.605      2.01
                OAK            0.840       0.670       1.010     22.17
        Imblaze 370            1.810       0.770       2.850      0.59
JAVELIN Gastric 300            1.220       0.855       1.585      4.81
Group: No            
                                                                      
              Study               HR    [95% Conf. Interval]  % Weight




Subgroup meta-analysis summary              Number of studies =     12
        Study label:  Study
          Std. Err.:  _meta_se
        Effect size:  OS_HR
  Effect-size label:  HR






Overall Survival for PD-L1 Negative Patients using 1% Threshold Across All Tumors 
grouped by Follow-up Duration (<18mon versus >18mon) 
 Test of group differences: Q_b = chi2(1) = 0.40            Prob > Q_b = 0.525
                                                                             
       Overall        11      16.99   0.108       0.000       0.00       1.00
                                                                             
           Yes         5       5.48   0.360       0.000       0.00       1.00
            No         5      11.43   0.043       0.041      54.35       2.19
                                                                             
         Group        df          Q   P > Q        tau2       % I2         H2
                                                                             
Heterogeneity summary
                                                                      
              theta            0.829       0.749       0.909
Overall              
                                                                      
              theta            0.821       0.725       0.918
                     
                OAK            0.840       0.670       1.010     22.17
        KEYNOTE 006            0.790       0.440       1.140      5.23
      Checkmate 067            0.770       0.525       1.015     10.68
       CheckMate 25            0.770       0.585       0.955     18.72
      CheckMate 141            0.730       0.430       1.030      7.12
JAVELIN Gastric 300            1.220       0.855       1.585      4.81
Group: Yes           
                                                                      
              theta            0.902       0.673       1.132
                     
             POPLAR            1.040       0.475       1.605      2.01
        KEYNOTE-061            1.200       0.830       1.570      4.68
        Imblaze 370            1.810       0.770       2.850      0.59
       CheckMate 57            0.900       0.610       1.190      7.62
      CheckMate 017            0.580       0.305       0.855      8.47
      CheckMate 078            0.750       0.465       1.035      7.89
Group: No            
                                                                      
              Study               HR    [95% Conf. Interval]  % Weight




Subgroup meta-analysis summary              Number of studies =     12
        Study label:  Study
          Std. Err.:  _meta_se
        Effect size:  OS_HR
  Effect-size label:  HR






Overall Survival for PD-L1 Negative Patients using 1% Threshold Across All Tumors 
grouped by Line of Therapy (1 Line versus Later Line) 
 Test of group differences: Q_b = chi2(1) = 0.51            Prob > Q_b = 0.473
                                                                             
       Overall        11      16.99   0.108       0.000       0.00       1.00
                                                                             
           Yes         1       0.01   0.927       0.000       0.00       1.00
            No         9      16.67   0.054       0.014      39.72       1.66
                                                                             
         Group        df          Q   P > Q        tau2       % I2         H2
                                                                             
Heterogeneity summary
                                                                      
              theta            0.829       0.749       0.909
Overall              
                                                                      
              theta            0.777       0.576       0.977
                     
        KEYNOTE 006            0.790       0.440       1.140      5.23
      Checkmate 067            0.770       0.525       1.015     10.68
Group: Yes           
                                                                      
              theta            0.863       0.740       0.985
                     
             POPLAR            1.040       0.475       1.605      2.01
                OAK            0.840       0.670       1.010     22.17
        KEYNOTE-061            1.200       0.830       1.570      4.68
        Imblaze 370            1.810       0.770       2.850      0.59
       CheckMate 57            0.900       0.610       1.190      7.62
       CheckMate 25            0.770       0.585       0.955     18.72
      CheckMate 017            0.580       0.305       0.855      8.47
      CheckMate 141            0.730       0.430       1.030      7.12
JAVELIN Gastric 300            1.220       0.855       1.585      4.81
      CheckMate 078            0.750       0.465       1.035      7.89
Group: No            
                                                                      
              Study               HR    [95% Conf. Interval]  % Weight




Subgroup meta-analysis summary              Number of studies =     12
        Study label:  Study
          Std. Err.:  _meta_se
        Effect size:  OS_HR
  Effect-size label:  HR






Overall Survival for PD-L1 Positive Patients using 1% Threshold Across All Tumors 




Test of group differences: Q_b = chi2(1) = 0.98            Prob > Q_b = 0.322
                                                                             
       Overall        15      31.53   0.007       0.011      55.56       2.25
                                                                             
           Yes        10      25.02   0.005       0.012      62.43       2.66
            No         4       4.55   0.337       0.005      23.92       1.31
                                                                             
         Group        df          Q   P > Q        tau2       % I2         H2
                                                                             
Heterogeneity summary
                                                                      
              theta            0.718       0.646       0.790
Overall              
                                                                      
              theta            0.700       0.613       0.786
                     
        KEYNOTE-042            0.810       0.700       0.920      9.84
        KEYNOTE-061            0.820       0.635       1.005      6.93
        KEYNOTE 010            0.660       0.560       0.760     10.25
        KEYNOTE 006            0.670       0.515       0.825      8.02
      Checkmate 067            0.530       0.380       0.680      8.22
       CheckMate 57            0.590       0.395       0.785      6.59
       CheckMate 26            1.070       0.835       1.305      5.41
       CheckMate 25            0.790       0.470       1.110      3.62
      CheckMate 017            0.690       0.390       0.990      3.97
      CheckMate 141            0.550       0.355       0.745      6.59
      CheckMate 078            0.620       0.410       0.830      6.12
Group: Yes           
                                                                      
              theta            0.776       0.653       0.899
                     
             POPLAR            0.590       0.365       0.815      5.68
                OAK            0.770       0.630       0.910      8.62
        Imblaze 370            0.800       0.310       1.290      1.85
JAVELIN Gastric 300            0.940       0.450       1.430      1.85
   JAVELIN Lung 200            0.900       0.700       1.100      6.43
Group: No            
                                                                      
              Study               HR    [95% Conf. Interval]  % Weight




Subgroup meta-analysis summary              Number of studies =     16
        Study label:  Study
          Std. Err.:  _meta_se
        Effect size:  OS_HR
  Effect-size label:  HR






Overall Survival for PD-L1 Positive Patients using 1% Threshold Across All Tumors 
grouped by Follow-up Duration (<18mon versus >18mon)
 Test of group differences: Q_b = chi2(1) = 0.15            Prob > Q_b = 0.695
                                                                             
       Overall        15      31.53   0.007       0.011      55.56       2.25
                                                                             
           Yes         6      13.28   0.039       0.012      56.24       2.29
            No         8      17.53   0.025       0.011      57.79       2.37
                                                                             
         Group        df          Q   P > Q        tau2       % I2         H2
                                                                             
Heterogeneity summary
                                                                      
              theta            0.718       0.646       0.790
Overall              
                                                                      
              theta            0.702       0.588       0.816
                     
                OAK            0.770       0.630       0.910      8.62
        KEYNOTE 006            0.670       0.515       0.825      8.02
      Checkmate 067            0.530       0.380       0.680      8.22
       CheckMate 25            0.790       0.470       1.110      3.62
      CheckMate 141            0.550       0.355       0.745      6.59
JAVELIN Gastric 300            0.940       0.450       1.430      1.85
   JAVELIN Lung 200            0.900       0.700       1.100      6.43
Group: Yes           
                                                                      
              theta            0.732       0.634       0.830
                     
             POPLAR            0.590       0.365       0.815      5.68
        KEYNOTE-042            0.810       0.700       0.920      9.84
        KEYNOTE-061            0.820       0.635       1.005      6.93
        KEYNOTE 010            0.660       0.560       0.760     10.25
        Imblaze 370            0.800       0.310       1.290      1.85
       CheckMate 57            0.590       0.395       0.785      6.59
       CheckMate 26            1.070       0.835       1.305      5.41
      CheckMate 017            0.690       0.390       0.990      3.97
      CheckMate 078            0.620       0.410       0.830      6.12
Group: No            
                                                                      
              Study               HR    [95% Conf. Interval]  % Weight




Subgroup meta-analysis summary              Number of studies =     16
        Study label:  Study
          Std. Err.:  _meta_se
        Effect size:  OS_HR
  Effect-size label:  HR






Overall Survival for PD-L1 Positive Patients using 1% Threshold Across All Tumors 




Test of group differences: Q_b = chi2(1) = 0.25            Prob > Q_b = 0.618
                                                                             
       Overall        15      31.53   0.007       0.011      55.56       2.25
                                                                             
           Yes         3      17.44   0.001       0.039      86.61       7.47
            No        11      13.39   0.269       0.003      23.73       1.31
                                                                             
         Group        df          Q   P > Q        tau2       % I2         H2
                                                                             
Heterogeneity summary
                                                                      
              theta            0.718       0.646       0.790
Overall              
                                                                      
              theta            0.759       0.548       0.970
                     
        KEYNOTE-042            0.810       0.700       0.920      9.84
        KEYNOTE 006            0.670       0.515       0.825      8.02
      Checkmate 067            0.530       0.380       0.680      8.22
       CheckMate 26            1.070       0.835       1.305      5.41
Group: Yes           
                                                                      
              theta            0.702       0.634       0.770
                     
             POPLAR            0.590       0.365       0.815      5.68
                OAK            0.770       0.630       0.910      8.62
        KEYNOTE-061            0.820       0.635       1.005      6.93
        KEYNOTE 010            0.660       0.560       0.760     10.25
        Imblaze 370            0.800       0.310       1.290      1.85
       CheckMate 57            0.590       0.395       0.785      6.59
       CheckMate 25            0.790       0.470       1.110      3.62
      CheckMate 017            0.690       0.390       0.990      3.97
      CheckMate 141            0.550       0.355       0.745      6.59
JAVELIN Gastric 300            0.940       0.450       1.430      1.85
      CheckMate 078            0.620       0.410       0.830      6.12
   JAVELIN Lung 200            0.900       0.700       1.100      6.43
Group: No            
                                                                      
              Study               HR    [95% Conf. Interval]  % Weight




Subgroup meta-analysis summary              Number of studies =     16
        Study label:  Study
          Std. Err.:  _meta_se
        Effect size:  OS_HR
  Effect-size label:  HR







Overall Survival by PD-L1 Positivity using 1% Threshold Across All Tumors with 
removal of CHECKMATE-026 study
 Test of group differences: Q_b = chi2(1) = 6.39            Prob > Q_b = 0.011
                                                                             
       Overall        26      47.00   0.007       0.008      40.36       1.68
                                                                             
           Yes        14      22.31   0.072       0.006      41.07       1.70
            No        11      16.99   0.108       0.000       0.00       1.00
                                                                             
         Group        df          Q   P > Q        tau2       % I2         H2
                                                                             
Heterogeneity summary
                                                                      
              theta            0.743       0.688       0.799
Overall              
                                                                      
              theta            0.698       0.634       0.761
                     
             POPLAR            0.590       0.365       0.815      3.91
                OAK            0.770       0.630       0.910      6.40
        KEYNOTE-042            0.810       0.700       0.920      7.57
        KEYNOTE-061            0.820       0.635       1.005      4.92
        KEYNOTE 010            0.660       0.560       0.760      7.98
        KEYNOTE 006            0.670       0.515       0.825      5.87
        Imblaze 370            0.800       0.310       1.290      1.16
      Checkmate 067            0.530       0.380       0.680      6.04
       CheckMate 57            0.590       0.395       0.785      4.64
       CheckMate 25            0.790       0.470       1.110      2.37
      CheckMate 017            0.690       0.390       0.990      2.61
      CheckMate 141            0.550       0.355       0.745      4.64
JAVELIN Gastric 300            0.940       0.450       1.430      1.16
      CheckMate 078            0.620       0.410       0.830      4.26
   JAVELIN Lung 200            0.900       0.700       1.100      4.51
Group: Yes           
                                                                      
              theta            0.829       0.749       0.909
                     
             POPLAR            1.040       0.475       1.605      0.89
                OAK            0.840       0.670       1.010      5.37
        KEYNOTE-061            1.200       0.830       1.570      1.87
        KEYNOTE 006            0.790       0.440       1.140      2.05
        Imblaze 370            1.810       0.770       2.850      0.28
      Checkmate 067            0.770       0.525       1.015      3.49
       CheckMate 57            0.900       0.610       1.190      2.75
       CheckMate 25            0.770       0.585       0.955      4.92
      CheckMate 017            0.580       0.305       0.855      2.97
      CheckMate 141            0.730       0.430       1.030      2.61
JAVELIN Gastric 300            1.220       0.855       1.585      1.92
      CheckMate 078            0.750       0.465       1.035      2.82
Group: No            
                                                                      
              Study               HR    [95% Conf. Interval]  % Weight




Subgroup meta-analysis summary              Number of studies =     27
        Study label:  Study
          Std. Err.:  _meta_se
        Effect size:  OS_HR
  Effect-size label:  HR







Overall Survival by PD-L1 Positivity using 5% Threshold Across All Tumors with 
removal of CHECKMATE-026 study
 
 
Test of group differences: Q_b = chi2(1) = 3.17            Prob > Q_b = 0.075
                                                                             
       Overall        14      34.95   0.001       0.024      62.16       2.64
                                                                             
           Yes         8      14.34   0.073       0.012      44.63       1.81
            No         5      15.72   0.008       0.038      71.10       3.46
                                                                             
         Group        df          Q   P > Q        tau2       % I2         H2
                                                                             
Heterogeneity summary
                                                                    
            theta            0.634       0.532       0.737
Overall            
                                                                    
            theta            0.559       0.450       0.667
                   
           POPLAR            0.540       0.260       0.820      6.14
              OAK            0.640       0.465       0.815      8.54
       Imvigor211            0.870       0.580       1.160      5.94
    Checkmate 067            0.630       0.360       0.900      6.34
    CheckMate 066            0.300       0.075       0.525      7.33
     CheckMate 57            0.430       0.265       0.595      8.78
    CheckMate 037            0.730       0.430       1.030      5.74
    CheckMate 017            0.530       0.240       0.820      5.94
    CheckMate 141            0.500       0.235       0.765      6.45
Group: Yes         
                                                                    
            theta            0.758       0.567       0.949
                   
    Checkmate 067            0.620       0.470       0.770      9.15
    CheckMate 066            0.480       0.285       0.675      8.05
     CheckMate 57            1.010       0.725       1.295      6.03
    CheckMate 037            1.150       0.750       1.550      4.14
    CheckMate 017            0.700       0.425       0.975      6.24
    CheckMate 141            0.810       0.480       1.140      5.20
Group: No          
                                                                    
            Study               HR    [95% Conf. Interval]  % Weight




Subgroup meta-analysis summary            Number of studies =     15
        Study label:  Study
          Std. Err.:  _meta_se
        Effect size:  OS_HR
  Effect-size label:  HR










Test of group differences: Q_b = chi2(1) = 0.52            Prob > Q_b = 0.470
                                                                             
       Overall        13      24.35   0.028       0.008      47.49       1.90
                                                                             
           Yes         8      19.56   0.012       0.011      61.87       2.62
            No         4       3.94   0.415       0.000       0.00       1.00
                                                                             
         Group        df          Q   P > Q        tau2       % I2         H2
                                                                             
Heterogeneity summary
                                                                    
            theta            0.755       0.682       0.828
Overall            
                                                                    
            theta            0.743       0.650       0.836
                   
           POPLAR            0.590       0.365       0.815      6.53
              OAK            0.770       0.630       0.910     10.51
      KEYNOTE-042            0.810       0.700       0.920     12.33
      KEYNOTE 010            0.660       0.560       0.760     12.96
     CheckMate 57            0.590       0.395       0.785      7.71
     CheckMate 26            1.070       0.835       1.305      6.18
    CheckMate 017            0.690       0.390       0.990      4.41
    CheckMate 078            0.620       0.410       0.830      7.09
 JAVELIN Lung 200            0.900       0.700       1.100      7.50
Group: Yes         
                                                                    
            theta            0.797       0.682       0.913
                   
           POPLAR            1.040       0.475       1.605      1.52
              OAK            0.840       0.670       1.010      8.88
     CheckMate 57            0.900       0.610       1.190      4.63
    CheckMate 017            0.580       0.305       0.855      5.00
    CheckMate 078            0.750       0.465       1.035      4.75
Group: No          
                                                                    
            Study               HR    [95% Conf. Interval]  % Weight




Subgroup meta-analysis summary            Number of studies =     14
        Study label:  Study
          Std. Err.:  _meta_se
        Effect size:  OS_HR
  Effect-size label:  HR





Progression Free Survival Results 
Table C-14  
Progression Free Survival by PD-L1 Positivity using 1% Threshold Across All Tumors
 Test of group differences: Q_b = chi2(1) = 3.47            Prob > Q_b = 0.062
                                                                             
       Overall        25     178.32   0.000       0.094      89.22       9.28
                                                                             
           Yes        14     114.22   0.000       0.057      87.67       8.11
            No        10      55.48   0.000       0.196      87.22       7.83
                                                                             
         Group        df          Q   P > Q        tau2       % I2         H2
                                                                             
Heterogeneity summary
                                                                      
              theta            0.911       0.777       1.046
Overall              
                                                                      
              theta            0.810       0.675       0.946
                     
             POPLAR            0.850       0.585       1.115      4.19
                OAK            0.870       0.725       1.015      4.73
        KEYNOTE-042            1.070       0.935       1.205      4.77
        KEYNOTE-061            1.270       1.000       1.540      4.16
        KEYNOTE 010            0.830       0.710       0.950      4.81
        KEYNOTE 006            0.540       0.435       0.645      4.86
        KEYNOTE-002            0.520       0.375       0.665      4.73
        Imblaze 370            0.710       0.315       1.105      3.49
      Checkmate 067            0.450       0.335       0.565      4.83
       CheckMate 57            0.700       0.495       0.905      4.48
       CheckMate 26            1.170       0.930       1.410      4.32
      CheckMate 017            0.670       0.385       0.955      4.09
      CheckMate 141            0.590       0.375       0.805      4.44
JAVELIN Gastric 300            1.750       0.755       2.745      1.34
   JAVELIN Lung 200            1.010       0.770       1.250      4.32
Group: Yes           
                                                                      
              theta            1.120       0.824       1.416
                     
             POPLAR            1.120       0.595       1.645      2.84
                OAK            1.110       0.905       1.315      4.48
        KEYNOTE-061            2.050       1.405       2.695      2.33
        KEYNOTE 006            0.870       0.510       1.230      3.68
        KEYNOTE-002            0.600       0.320       0.880      4.11
        Imblaze 370            2.170       1.030       3.310      1.09
      Checkmate 067            0.590       0.410       0.770      4.59
       CheckMate 57            1.190       0.825       1.555      3.66
      CheckMate 017            0.660       0.375       0.945      4.09
      CheckMate 141            1.130       0.650       1.610      3.06
JAVELIN Gastric 300            1.950       1.355       2.545      2.53
Group: No            
                                                                      
              Study               HR    [95% Conf. Interval]  % Weight




Subgroup meta-analysis summary              Number of studies =     26
        Study label:  Study
          Std. Err.:  _meta_se
        Effect size:  PFS_HR
  Effect-size label:  HR






PFS by PD-L1 Positivity using 1% Threshold Across All Tumors 
 















Test of group differences: Q_b = chi2(1) = 0.26            Prob > Q_b = 0.610
                                                                             
       Overall         9      45.83   0.000       0.066      83.99       6.25
                                                                             
           Yes         6      28.67   0.000       0.057      80.34       5.09
            No         2      17.12   0.000       0.134      89.73       9.73
                                                                             
         Group        df          Q   P > Q        tau2       % I2         H2
                                                                             
Heterogeneity summary
                                                                    
            theta            0.751       0.572       0.930
Overall            
                                                                    
            theta            0.718       0.515       0.921
                   
           POPLAR            0.720       0.255       1.185      6.85
              OAK            0.730       0.555       0.905     11.35
       Imvigor211            1.010       0.715       1.305      9.46
    Checkmate 067            0.420       0.250       0.590     11.42
     CheckMate 57            0.540       0.355       0.725     11.21
     CheckMate 26            1.150       0.880       1.420      9.88
    CheckMate 017            0.540       0.250       0.830      9.55
Group: Yes         
                                                                    
            theta            0.844       0.403       1.285
                   
    Checkmate 067            0.540       0.415       0.665     11.99
     CheckMate 57            1.310       0.960       1.660      8.57
    CheckMate 017            0.750       0.470       1.030      9.71
Group: No          
                                                                    
            Study               HR    [95% Conf. Interval]  % Weight




Subgroup meta-analysis summary            Number of studies =     10
        Study label:  Study
          Std. Err.:  _meta_se
        Effect size:  PFS_HR
  Effect-size label:  HR






PFS by PD-L1 Positivity using 5% Threshold Across All Tumors 
 






















Test of group differences: Q_b = chi2(1) = 1.01            Prob > Q_b = 0.316
                                                                             
       Overall         6      22.61   0.001       0.050      79.98       4.99
                                                                             
           Yes         3       4.70   0.195       0.007      29.91       1.43
            No         2      17.50   0.000       0.118      90.46      10.48
                                                                             
         Group        df          Q   P > Q        tau2       % I2         H2
                                                                             
Heterogeneity summary
                                                                    
            theta            0.677       0.486       0.869
Overall            
                                                                    
            theta            0.573       0.420       0.727
                   
    Checkmate 072            0.460       0.240       0.680     15.27
     CheckMate 57            0.520       0.330       0.710     16.10
    CheckMate 017            0.580       0.235       0.925     11.81
      KEYNOTE-045            0.890       0.555       1.225     12.07
Group: Yes         
                                                                    
            theta            0.799       0.386       1.211
                   
    Checkmate 074            0.520       0.410       0.630     17.99
     CheckMate 57            1.240       0.915       1.565     12.34
    CheckMate 017            0.700       0.450       0.950     14.43
Group: No          
                                                                    
            Study               HR    [95% Conf. Interval]  % Weight




Subgroup meta-analysis summary            Number of studies =      7
        Study label:  Study
          Std. Err.:  _meta_se
        Effect size:  PFS_HR
  Effect-size label:  HR






PFS by PD-L1 Positivity using 10% Threshold Across All Tumors 
 



























     Prob > |z| =    0.0467
              z =      1.99
    SE of score =    14.583
Kendall's score =     30.00
Begg's test for small-study effects
(1 missing value generated)
(1 missing value generated)
          Std. Err.:  _meta_se
        Effect size:  OS_HR
  Effect-size label:  HR
. meta bias, begg
     Prob > |z| =    0.3914
              z =      0.86
    SE of score =    22.166
Kendall's score =     20.00
Begg's test for small-study effects
(1 missing value generated)
(1 missing value generated)
          Std. Err.:  _meta_se
        Effect size:  OS_HR
  Effect-size label:  HR














     Prob > |z| =    0.0195
              z =      2.34
    SE of score =    12.845
Kendall's score =     31.00
Begg's test for small-study effects
(2 missing values generated)
(2 missing values generated)
          Std. Err.:  _meta_se
        Effect size:  PFS_HR
  Effect-size label:  Effect Size
. meta bias, begg
     Prob > |z| =    0.1971
              z =      1.29
    SE of score =    20.158
Kendall's score =     27.00
Begg's test for small-study effects
(2 missing values generated)
(2 missing values generated)
          Std. Err.:  _meta_se
        Effect size:  PFS_HR
  Effect-size label:  HR
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